Select Earlier Investments
The general partners, prior to SVP III, are proud to have invested in the following select companies:
Alacritech continues to license its patented accelerator technology, but is no longer manufacturing the ANX series of NFS accelerators. ANX customers will continue to receive strong support through a special team which has been put in place to assure that support contracts are fully met.
Layer 7 Technologies
Through its award-winning line of SOA Gateways, Cloud Brokers and API Proxies, Layer 7 gave enterprises the ability to control identity, data security, SLA and visibility requirements for sharing application data and functionality across organizational boundaries. In 2011, Layer 7 was named the 71st fastest-growing private or public technology company in North America on the Deloitte Fast 500 list. With more than 150 customers spanning six continents, Layer 7 supported the most demanding commercial and government organizations. Layer 7 solutions are FIPS compliant, STIG vulnerability tested and have met Common Criteria EAL4+ security assurance.
PatientSafe delivers measurable safety and quality improvements through a mobile platform that extends an organization’s EMR, clinical, and communication infrastructure and fits seamlessly into care team workflows.
PatientSafe’s context-driven PatientTouch® platform unifies communication with workflow by consolidating text, talk, alerts, EMR data, and clinical workflows all in one mobile app, on one device. For more than a decade, PatientTouch has helped clinicians both in and outside the hospital streamline care delivery, increase quality and lower costs.
Current Investments (SVP III)
CoinFlip is a conversion and payment platform technology solution that enables consumers to use their loyalty points and miles for purchases at brick-and-mortar retail locations. CoinFlip’s proprietary technology facilitates conversion of points and miles to payment transactions, simplifies the transactional accounting, and provides access to valuable data streams.
DBM Cloud Systems
DBM Cloud Systems provides software for the management of Cloud data in a hybrid and multi-Cloud environment. DBM solves three key challenges including 1) the technical challenge of efficiently moving data between Clouds to access desired services, 2) the financial problem of getting locked into a single Cloud vendor who may not provide the lowest cost services and 3) the policy compliance challenge of making sure your data resides where it should due to legal constraints or corporate policy.
Microdermics is a Vancouver-based medical device company focused on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. Microdermics’ platform aims to revolutionize the traditional hypodermic needle-based drug injection by increasing efficiency, eliminating pain, and improving personnel and patient safety.
Zomanex Canada is a worldwide licensee of IP to convert certain IV-administered drugs to oral delivery. The lead candidates are oral versions of paclitaxel and docetaxel, two frontline oncology drugs used in the treatment of various cancers including ovarian, lung and breast cancer. Zomanex Canada has the exclusive worldwide license to develop and market the drugs and a first option to negotiate other molecules. The licensor, Zomanex USA, is a Shoreline II company.